To: Buckey who wrote (89393 ) 1/18/2005 10:42:47 PM From: scion Read Replies (4) | Respond to of 122087 Sandy Winick, President, HEE Corporation said they expect to start licensing the treatments once the first group of patients has successfully received the treatment, which will be administered at a United States university or medical institution. The treatment could be available by the summer of 2004. Mellon Research, Inc. Invested In Diabetes Prevention Tuesday January 18, 2:59 PM EST SCOTTSDALE, Ariz., Jan 18, 2005 (BUSINESS WIRE) -- Mellon Research, Inc. (MLON) the market leader in providing boutique micro-cap venture capital services to private mid cap companies is pleased to announce financing to build and develop the complete infrastructure of HEE Corporation (HCCF) in the amount of $200,000 in equity and cash from various investors. Mellon has received compensation in the form of stock from HEE Corporation. "We have examined numerous products in the diabetes prevention arena and have decided to support HEE Corporation (HCCF) to grow HEE Corporation as the pre-eminent producer of type two diabetes prevention here in the United States and further abroad as well." Quoted Mario Pino CEO of Mellon Research. "Type two diabetes plagues many families in America and we believe this wellness product could provide an alternative to present products available in the market. A significant change in managed care can be made in America with this winning formula that changes the health and wellness of Americans of all ages." HEE Corporation (HCCF.PK) Announces That It Has Signed A World-Wide Exclusive Distribution Agreement With Thomlinson Trade & Investments, Inc. For The Treatment Of Type 2 Diabetes TORONTO, Feb. 25 /PRNewswire-FirstCall/ -- The Board of Directors of HEE Corporation - (OTC - PK - HCCF) is extremely pleased to announce that the company has signed a world wide exclusive distribution agreement with Thomlinson Trade & Investments, Inc. of Switzerland for a revolutionary medical procedure for the treatment of Type-2 Diabetes. The signing of the distribution agreement grants HEE Corporation world wide exclusivity for this new procedure. Sandy Winick, President, HEE Corporation said they expect to start licensing the treatments once the first group of patients has successfully received the treatment, which will be administered at a United States university or medical institution. The treatment could be available by the summer of 2004. HEE Corporation has been engaged in the discovery and development of a novel and superior treatment for millions of patients with this form of diabetes worldwide. The formulation for the treatment -- which has been actively developed over the past several years -- has proved itself as an effective remedy to Type 2 Diabetes on a limited number of patients. The next stage is to have the treatment tested by an independent facility. A number of facilities have been identified in North America and Europe, and a decision will be made in the next few weeks for this very important next step. The Company will make public additional information as and when it becomes available to keep the public informed of this very significant medical discovery. NOTE: Safe Harbor for Forward-Looking Statements--Except for historical information contained herein, the statements in this news release are forward- looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that may cause the company's actual results in the future to differ materially from forecasted results. These risks and uncertainties include, among other things, volatility of prices, product demand, market compensation and risk inherent in the company's international operations. HEE Corporation CONTACT: about the Company contact Sandy Winick @ 416-918-2209 orvisit our web site at hee-corp.com biospace.com